Infectious diseases biobanking as a catalyst towards personalized medicine: Mycobacterium tuberculosis paradigm.

Research for biomarkers supporting personalized medicine in infectious diseases is needed, especially for tuberculosis in which the existing toolbox does not yet address the public health priorities. Biobanks are essential infrastructures in this effort by collecting, authenticating and preserving human and/or bacterial specimens. A broad range of specimens should be collected prior to, during and following treatment, with a comprehensive characterisation of the sample donors and the samples themselves to accommodate the most recent technological platforms in biomarker research. This review explains current state-of-the-field biobanking practices in tuberculosis and suggests technical and managerial improvements to ensure long-term preservation and optimal use of the specimens. Open-access and certified biobanks are an essential component of a strategy supporting the development of drugs and diagnostic tests for both public health and personalised medicine. Biobanks have a role to play in the interaction between these two - not always compatible - approaches.

[1]  A. Diacon,et al.  Differential cytokine/chemokines and KL-6 profiles in patients with different forms of tuberculosis. , 2009, Cytokine.

[2]  R. Gie,et al.  Immune parameters as markers of tuberculosis extent of disease and early prediction of anti-tuberculosis chemotherapy response. , 2008, The Journal of infection.

[3]  J. Yim,et al.  INVITED REVIEW SERIES: TUBERCULOSIS , 2010 .

[4]  Dirk Repsilber,et al.  Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis , 2007, Journal of Molecular Medicine.

[5]  Fay Betsou,et al.  Biobanking for better healthcare , 2008, Molecular oncology.

[6]  T. Bodmer,et al.  Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis , 2008, European Respiratory Journal.

[7]  John L. Johnson,et al.  Sputum Cytokine Levels in Patients with Pulmonary Tuberculosis as Early Markers of Mycobacterial Clearance , 2002, Clinical and Vaccine Immunology.

[8]  D Repsilber,et al.  Human gene expression profiles of susceptibility and resistance in tuberculosis , 2011, Genes and Immunity.

[9]  Virginia Pascual,et al.  An Interferon-Inducible Neutrophil-Driven Blood Transcriptional Signature in Human Tuberculosis , 2010, Nature.

[10]  F. Betsou,et al.  Standard Preanalytical Coding for Biospecimens: Defining the Sample PREanalytical Code , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[11]  E. Diamandis,et al.  Cancer biomarkers: can we turn recent failures into success? , 2010, Journal of the National Cancer Institute.

[12]  F. Betsou,et al.  Soluble CD40 ligand as a biomarker for storage-related preanalytic variations of human serum. , 2008, Cytokine.

[13]  F. Betsou,et al.  Quality assurance in cancer biobanking. , 2011, Biopreservation and biobanking.

[14]  H. E. Solberg.  Approved recommendation (1987) on the theory of reference values. Part 5. Statistical treatment of collected reference values. Determination of reference limits , 1987 .

[15]  A. Franke,et al.  A functional haplotype in the 3'untranslated region of TNFRSF1B is associated with tuberculosis in two African populations. , 2010, American journal of respiratory and critical care medicine.

[16]  K. Stowman.  World health statistics. , 1949, The Milbank Memorial Fund quarterly.

[17]  H. Dockrell,et al.  Biomarkers for TB treatment response: challenges and future strategies. , 2008, The Journal of infection.

[18]  Joel S. Freundlich,et al.  Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery. , 2011, Trends in Microbiology.

[19]  D. Hunt,et al.  Biological safety : principles and practices , 2006 .

[20]  M. Herbster,et al.  Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum , 2006, The Lancet.

[21]  P. V. van Helden,et al.  Differential Expression of Interleukin-4 (IL-4) and IL-4δ2 mRNA, but Not Transforming Growth Factor Beta (TGF-β), TGF-βRII, Foxp3, Gamma Interferon, T-bet, or GATA-3 mRNA, in Patients with Fast and Slow Responses to Antituberculosis Treatment , 2008, Clinical and Vaccine Immunology.

[22]  K. Lai,et al.  Elevated interleukin-2 receptor level in patients with active pulmonary tuberculosis and the changes following anti-tuberculosis chemotherapy. , 1995, The European respiratory journal.

[23]  S. Kaufmann,et al.  Identification of T-Cell Antigens Specific for Latent Mycobacterium Tuberculosis Infection , 2009, PloS one.

[24]  S. Gillespie,et al.  Biomarkers of treatment response in clinical trials of novel antituberculosis agents. , 2007, The Lancet. Infectious diseases.

[25]  Thomas Burke,et al.  Human Biospecimen Research: Experimental Protocol and Quality Control Tools , 2009, Cancer Epidemiology Biomarkers & Prevention.

[26]  A. Hess,et al.  Descriptive proteomic analysis shows protein variability between closely related clinical isolates of Mycobacterium tuberculosis , 2010, Proteomics.

[27]  Xinjing Wang,et al.  Association of mycobacterial antigen-specific CD4(+) memory T cell subsets with outcome of pulmonary tuberculosis. , 2010, The Journal of infection.

[28]  Paul D van Helden,et al.  Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis. , 2007, The Journal of infectious diseases.

[29]  Alimuddin Zumla,et al.  Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice , 2010, The Lancet.

[30]  R. Kush,et al.  Global clinical data interchange standards are here! , 2007, Drug discovery today.

[31]  F. Betsou,et al.  Immunological Fingerprinting Method for Differentiation of Serum Samples in Research-Oriented Biobanks , 2010, Clinical and Vaccine Immunology.

[32]  C. Saltini,et al.  Soluble immunological markers of disease activity in tuberculosis. , 1999, The European respiratory journal.

[33]  P. V. van Helden,et al.  TB epidemiology and human genetics. , 2006, Novartis Foundation symposium.

[34]  S. Gagneux,et al.  Does M. tuberculosis genomic diversity explain disease diversity? , 2010, Drug discovery today. Disease mechanisms.

[35]  Hongzhou Lu,et al.  SLC11A1 (NRAMP1) Polymorphisms and Tuberculosis Susceptibility: Updated Systematic Review and Meta-Analysis , 2011, PloS one.